+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Musculoskeletal System Disorder Drug Market - Global Forecast 2026-2032- Product Image
Musculoskeletal System Disorder Drug Market - Global Forecast 2026-2032- Product Image
Sale

Musculoskeletal System Disorder Drug Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6123770
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Musculoskeletal System Disorder Drug Market is projected to reach USD 95.69 Billion in 2026. It is expected to continue growing at a CAGR of 4.56%, reaching USD 125.48 Billion by 2032.

Musculoskeletal Disorder Drugs: Executive Summary

Musculoskeletal disorder drugs address conditions affecting bones, joints, muscles, connective tissue, and related pain or inflammation. The therapeutic landscape spans analgesics, anti-inflammatory medicines, disease-modifying treatments, corticosteroids, biologics, bone-health therapies, and products used in rehabilitation-linked care. Demand is shaped by aging populations, chronic pain, autoimmune disease, osteoporosis, injury, occupational strain, and expanding attention to functional independence and quality of life.

Care Is Shifting Toward Earlier, More Integrated Intervention

Treatment is moving from episodic symptom relief toward earlier diagnosis, risk stratification, multimodal care, and longer-term disease management. Clinicians increasingly balance efficacy with gastrointestinal, cardiovascular, renal, hepatic, infection, and dependency risks. Nonpharmacological treatment, physical rehabilitation, surgery, and digital monitoring are being combined with medicines, while access initiatives emphasize essential therapies, biosimilars, generic substitution, and more consistent adherence. Regulatory and clinical expectations also increasingly favor evidence on function, safety, patient-reported outcomes, and real-world durability.

Artificial Intelligence Strengthens Diagnosis, Development, and Treatment Optimization

Artificial intelligence can support musculoskeletal care by identifying patterns in radiology, pathology, clinical notes, and longitudinal records; improving triage; and helping clinicians distinguish inflammatory, degenerative, traumatic, and neuropathic presentations. In drug development, machine learning can assist target identification, trial recruitment, safety-signal detection, endpoint analysis, and selection of patients most likely to respond. Responsible implementation requires representative data, external validation, explainability, privacy safeguards, cybersecurity, human oversight, and monitoring for bias. AI is most valuable when integrated into clinical workflows rather than treated as a replacement for professional judgment.

Regional Insights: Uneven Access Meets Broad Clinical Need

North America combines advanced diagnostics, specialist capacity, and extensive use of innovative therapies with persistent affordability, opioid-stewardship, and access concerns. Europe emphasizes evidence-based prescribing, health-technology assessment, biosimilar adoption, and coordinated management of chronic disease. Asia-Pacific presents strong variation in income, healthcare infrastructure, regulatory maturity, and rural access, alongside substantial needs related to aging, injury, and occupational disease. Latin America is shaped by uneven insurance coverage, public-sector procurement, generic utilization, and specialist concentration in major cities. The Middle East is investing in healthcare modernization while addressing differences in coverage, workforce, and chronic disease burden. Africa faces constraints in diagnosis, medicine availability, specialist care, and supply continuity, making primary-care integration and essential-medicine access especially important.

Group Insights: Cooperation and Policy Shape Treatment Access

ASEAN markets require adaptable access strategies because regulatory systems, reimbursement arrangements, and care capacity differ substantially across member states. BRICS economies combine large and diverse patient populations with varied domestic manufacturing, procurement, and clinical research capabilities. The European Union benefits from regulatory coordination but continues to navigate national reimbursement decisions and unequal access between member states. G7 systems generally possess strong research and clinical infrastructure while confronting aging-related demand, budget pressure, and safety oversight. GCC countries are strengthening specialized care and health-system modernization, with procurement coordination and workforce development remaining important. NATO members span different health systems, yet resilience, continuity of supply, emergency preparedness, and treatment access are shared priorities.

Country Insights: Distinct Systems Require Localized Strategies

Australia combines universal coverage with geographic access challenges and a strong need for coordinated chronic-care and rural services. Brazil’s scale and regional inequality make public procurement, primary-care integration, and affordable generics central considerations. Canada faces dispersed populations, provincial variation, and access challenges for specialists and advanced therapies. China is expanding healthcare capacity and domestic innovation while managing regional disparities and reimbursement priorities. France, Germany, Italy, and Spain pair established clinical systems with aging populations, cost-effectiveness scrutiny, and differing national access pathways. India’s large burden of pain, injury, and chronic disease coexists with uneven insurance coverage, specialist availability, and medicine affordability. Japan and South Korea emphasize aging-related care, advanced clinical infrastructure, and pressure to manage long-term healthcare costs. Mexico continues to address fragmentation, regional inequity, and access to specialist diagnosis. Russia’s treatment environment is influenced by domestic supply, healthcare-system resilience, and geographic access. The United Kingdom balances universal coverage with evidence assessment, waiting-time pressures, and constrained service capacity. The United States offers broad therapeutic choice and research strength but faces high out-of-pocket costs, unequal access, opioid-related safeguards, and complex reimbursement.

Leadership Priorities for Safer, More Accessible Musculoskeletal Care

Industry leaders should prioritize therapies with meaningful functional benefits, clear safety differentiation, and evidence across diverse patient populations. They should strengthen patient-support programs, adherence tools, and appropriate-use education without encouraging unnecessary medication use. Local access planning should account for reimbursement, procurement, supply continuity, pharmacovigilance, and regulatory requirements rather than relying on a single global model. Partnerships with health systems can improve early diagnosis, referral pathways, rehabilitation integration, and outcome measurement. Organizations adopting AI should establish governance covering data quality, clinical validation, transparency, security, accountability, and post-deployment monitoring. Portfolio and operational decisions should also consider generic and biosimilar competition, manufacturing resilience, environmental responsibilities, and equitable access.

Research Methodology: Evidence-Based Synthesis of the Therapeutic Landscape

This executive summary uses a structured qualitative synthesis of the musculoskeletal disorder drug landscape. The assessment considers disease burden drivers, therapeutic classes, clinical practice, safety considerations, access conditions, health-system organization, regulatory and reimbursement context, digital transformation, and regional variation. Regional, group, and country comparisons are framed around documented healthcare-system characteristics and treatment-access factors. Insights should be validated against current regulatory decisions, clinical guidelines, peer-reviewed literature, public-health statistics, reimbursement policies, and pharmacovigilance data before being used for investment, clinical, or commercial decisions. No market estimates, market shares, forecasts, or company-specific claims are included.

Conclusion: Better Outcomes Depend on Integrated, Evidence-Led Care

The musculoskeletal disorder drug landscape is being reshaped by chronic disease, aging, treatment-safety expectations, unequal access, and the integration of medicines with rehabilitation and digital care. Artificial intelligence can improve identification, development, and personalization, but only when supported by rigorous validation and governance. The most durable progress will come from combining clinically meaningful innovation with affordability, resilient supply, responsible prescribing, and regionally appropriate delivery models. Leaders that measure function, safety, equity, and patient experience alongside clinical response will be better positioned to support sustainable improvements in musculoskeletal health.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Musculoskeletal System Disorder Drug Market, by Drug Class
7.1. Introduction
7.2. Biologics
7.3. Corticosteroids
7.4. Disease Modifying Antirheumatic Drugs
7.5. Nonsteroidal Anti-Inflammatory Drugs
8. Musculoskeletal System Disorder Drug Market, by Indication
8.1. Introduction
8.2. Ankylosing Spondylitis
8.3. Osteoarthritis
8.4. Psoriatic Arthritis
8.5. Rheumatoid Arthritis
9. Musculoskeletal System Disorder Drug Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
9.4. Topical
9.4.1. Cream
9.4.2. Gel
10. Musculoskeletal System Disorder Drug Market, by Dosage Form
10.1. Introduction
10.2. Capsule
10.3. Gel
10.4. Injectable
10.4.1. Intravenous
10.4.2. Subcutaneous
10.5. Tablet
11. Musculoskeletal System Disorder Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Musculoskeletal System Disorder Drug Market, by End User
12.1. Introduction
12.2. Ambulatory Surgery Centers
12.3. Clinics
12.4. Homecare Settings
12.5. Hospitals
13. Musculoskeletal System Disorder Drug Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Musculoskeletal System Disorder Drug Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Musculoskeletal System Disorder Drug Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. Astellas Pharma
17.4. AstraZeneca plc
17.5. Bayer AG
17.6. Biogen Inc.
17.7. Bristol-Myers Squibb Company
17.8. Celgene Corporation
17.9. Daiichi Sankyo Company, Ltd.
17.10. Eli Lilly and Company
17.11. Gilead Sciences, Inc.
17.12. GlaxoSmithKline plc
17.13. Horizon Therapeutics plc
17.14. Johnson & Johnson
17.15. Merck & Co., Inc.
17.16. Novartis AG
17.17. Pfizer Inc.
17.18. Regeneron Pharmaceuticals, Inc.
17.19. Roche Holding AG
17.20. Sanofi S.A.
17.21. Sun Pharmaceutical Industries Ltd.
17.22. Takeda Pharmaceutical Company Limited
17.23. Teva Pharmaceutical Industries Ltd.
17.24. UCB S.A.
17.25. Viatris
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Musculoskeletal System Disorder Drug Market, Years Considered for the Study
FIGURE 2. Global Musculoskeletal System Disorder Drug Market, Research Design
FIGURE 3. Global Musculoskeletal System Disorder Drug Market, Research Framework
FIGURE 4. Global Musculoskeletal System Disorder Drug Market, Data Triangulation
FIGURE 5. Global Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Musculoskeletal System Disorder Drug Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Musculoskeletal System Disorder Drug Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 13. Global Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Musculoskeletal System Disorder Drug Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Musculoskeletal System Disorder Drug Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Musculoskeletal System Disorder Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Musculoskeletal System Disorder Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Musculoskeletal System Disorder Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Musculoskeletal System Disorder Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Musculoskeletal System Disorder Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Musculoskeletal System Disorder Drug Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Musculoskeletal System Disorder Drug Market Segmentation & Coverage
TABLE 2. Global Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Disease Modifying Antirheumatic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Disease Modifying Antirheumatic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Disease Modifying Antirheumatic Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Ankylosing Spondylitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Ankylosing Spondylitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Ankylosing Spondylitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Osteoarthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Osteoarthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Osteoarthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Psoriatic Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Psoriatic Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Psoriatic Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 30. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Cream Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Cream Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Cream Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Gel Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Gel Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Gel Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 58. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Gel Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Gel Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Gel Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Global Ambulatory Surgery Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Ambulatory Surgery Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Ambulatory Surgery Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Musculoskeletal System Disorder Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. North America Musculoskeletal System Disorder Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. North America Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 113. North America Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. North America Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. North America Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 116. North America Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 117. North America Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 118. North America Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 119. North America Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 120. North America Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. North America Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Latin America Musculoskeletal System Disorder Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Latin America Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 124. Latin America Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 125. Latin America Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. Latin America Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 127. Latin America Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 128. Latin America Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 129. Latin America Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 130. Latin America Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 131. Latin America Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. Latin America Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Europe Musculoskeletal System Disorder Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Europe Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 135. Europe Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 136. Europe Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 137. Europe Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 138. Europe Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 139. Europe Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 140. Europe Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 141. Europe Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 142. Europe Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. Europe Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. Middle East Musculoskeletal System Disorder Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Middle East Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 146. Middle East Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. Middle East Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 148. Middle East Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 149. Middle East Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 150. Middle East Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 151. Middle East Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 152. Middle East Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 153. Middle East Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Middle East Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Africa Musculoskeletal System Disorder Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Africa Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 157. Africa Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. Africa Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 159. Africa Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 160. Africa Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 161. Africa Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 162. Africa Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 163. Africa Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 164. Africa Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. Africa Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. Global Musculoskeletal System Disorder Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. ASEAN Musculoskeletal System Disorder Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. ASEAN Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 169. ASEAN Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. ASEAN Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. ASEAN Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 172. ASEAN Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 173. ASEAN Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 174. ASEAN Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 175. ASEAN Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 176. ASEAN Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. ASEAN Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. GCC Musculoskeletal System Disorder Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. GCC Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 180. GCC Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 181. GCC Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 182. GCC Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 183. GCC Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 184. GCC Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 185. GCC Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 186. GCC Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 187. GCC Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. GCC Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. European Union Musculoskeletal System Disorder Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. European Union Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 191. European Union Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 192. European Union Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 193. European Union Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 194. European Union Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 195. European Union Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 196. European Union Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 197. European Union Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 198. European Union Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. European Union Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. BRICS Musculoskeletal System Disorder Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 201. BRICS Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 202. BRICS Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 203. BRICS Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 204. BRICS Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 205. BRICS Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 206. BRICS Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 207. BRICS Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 208. BRICS Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 209. BRICS Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. BRICS Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. G7 Musculoskeletal System Disorder Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. G7 Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 213. G7 Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. G7 Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. G7 Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 216. G7 Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 217. G7 Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 218. G7 Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 219. G7 Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 220. G7 Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. G7 Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. NATO Musculoskeletal System Disorder Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 223. NATO Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 224. NATO Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. NATO Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 226. NATO Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 227. NATO Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 228. NATO Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 229. NATO Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 230. NATO Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 231. NATO Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. NATO Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Global Musculoskeletal System Disorder Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 234. United States Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 235. United States Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 236. United States Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 237. United States Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 238. United States Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 239. United States Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 240. United States Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 241. United States Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. United States Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 243. United States Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. United States Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. Canada Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 246. Canada Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 247. Canada Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 248. Canada Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 249. Canada Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 250. Canada Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 251. Canada Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 252. Canada Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 253. Canada Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 254. Canada Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Canada Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. Mexico Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 257. Mexico Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 258. Mexico Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 259. Mexico Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 260. Mexico Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 261. Mexico Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 262. Mexico Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 263. Mexico Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 264. Mexico Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 265. Mexico Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Mexico Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. Brazil Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 268. Brazil Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 269. Brazil Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 270. Brazil Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 271. Brazil Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 272. Brazil Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 273. Brazil Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 274. Brazil Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 275. Brazil Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 276. Brazil Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Brazil Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 278. United Kingdom Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 279. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 280. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 281. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 282. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 283. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 284. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 285. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 286. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 287. United Kingdom Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 288. United Kingdom Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. Germany Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 290. Germany Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 291. Germany Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 292. Germany Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 293. Germany Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 294. Germany Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 295. Germany Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 296. Germany Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 297. Germany Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 298. Germany Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Germany Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 300. France Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 301. France Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 302. France Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 303. France Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 304. France Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 305. France Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 306. France Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 307. France Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 308. France Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 309. France Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 310. France Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. Russia Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 312. Russia Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 313. Russia Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 314. Russia Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 315. Russia Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 316. Russia Musculoskeletal System Disorder Drug Market Size, by Oral, 2017-2032 (USD Million)
TABLE 317. Russia Musculoskeletal System Disorder Drug Market Size, by Topical, 2017-2032 (USD Million)
TABLE 318. Russia Musculoskeletal System Disorder Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 319. Russia Musculoskeletal System Disorder Drug Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 320. Russia Musculoskeletal System Disorder Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 321. Russia Musculoskeletal System Disorder Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 322. Italy Musculoskeletal System Disorder Drug Market Size, 2017-2032 (USD Million)
TABLE 323. Italy Musculoskeletal System Disorder Drug Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 324. Italy Musculoskeletal System Disorder Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 325. Italy Musculoskeletal System Disorder Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 326. Italy Musculoskeletal

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Viatris

Related Topics

Related Reports

Musculoskeletal System Disorder Therapeutics Market - Global Forecast 2026-2032 - Product Image

Musculoskeletal System Disorder Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Triamcinolone Market - Global Forecast 2026-2032 - Product Image

Triamcinolone Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Musculoskeletal Pain - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Musculoskeletal Pain - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Generic Musculoskeletal Disorders Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Generic Musculoskeletal Disorders Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Muscle Relaxant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Muscle Relaxant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 114 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.